Drug Trial Radar · NCT06876714
ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Trastuzumab
Last checked: Nov 20, 2026Latest source record: Oct 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
1,524
Planned (sponsor's estimate)
Start
Sep 17, 2025
Primary completion
Mar 13, 2028
Study completion Mar 13, 2037
Sponsor
- Lead sponsor
- Alliance for Clinical Trials in OncologyAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- National Cancer Institute (NCI)
- First posted
- Mar 14, 2025
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This phase III trial compares 6 months of human epidermal growth factor receptor 2 (HER2)-targeted therapy to 12 months of HER2-targeted therapy for the treatment of HER2-positive (+) breast cancer in patients that had a pathologic complete response (pCR) after preoperative (neoadjuvant) chemotherapy with trastuzumab. Trastuzumab and pertuzumab are monoclonal antibodies and forms of targeted therapy that attach to a receptor protein called HER2. HER2 is found on some cancer cells. When trastuzumab or pertuzumab attach to HER2, the signals that tell the cells to grow are blocked and the tumor cell may be marked for destruction by the body's immune system. Giving 6 months of HER2-targeted therapy may work better than giving 12 months for the treatment of HER2+ breast cancer in patients that had a pCR after neoadjuvant chemotherapy with trastuzumab.
Conditions
- Anatomic Stage I Breast Cancer AJCC v8
- Anatomic Stage II Breast Cancer AJCC v8
- Early Stage HER2+ Breast Cancer
Interventions
Trastuzumab (Herceptin)Biological
Given IV or SC
PertuzumabBiological
Given IV or SC
EchocardiographyProcedure
Undergo ECHO
Multigated Acquisition ScanProcedure
Undergo MUGA
MammographyProcedure
Undergo mammography
UltrasoundProcedure
Undergo ultrasound
Magnetic Resonance ImagingProcedure
Undergo MRI
Biospecimen CollectionProcedure
Undergo blood and tissue sample collection
Questionnaire AdministrationOther
Ancillary studies
Primary outcomes
What the sponsor says the trial is designed to measure.
- Recurrence-free survival (RFS)Time frame: From randomization to invasive local, regional or distant breast cancer recurrence, or death from any cause prior to a documented disease recurrence, assessed up to 10 years
- Functional Assessment of Cancer Therapy-Breast (FACT-B) total score (Quality of life)Time frame: At 12 months
Locations
702 sites in 2 countries. Site status is shown where the registry gives one.
Cancer Center at Saint Joseph's
Phoenix, Arizona · Suspended
Mayo Clinic Hospital in Arizona
Phoenix, Arizona · Recruiting
Mercy Hospital Fort Smith
Fort Smith, Arkansas · Suspended
NEA Baptist Memorial Hospital and Fowler Family Cancer Center - Jonesboro
Jonesboro, Arkansas · Recruiting
CARTI Cancer Center
Little Rock, Arkansas · Suspended
Mission Hope Medical Oncology - Arroyo Grande
Arroyo Grande, California · Suspended
Tower Cancer Research Foundation
Beverly Hills, California · Recruiting
Mercy Cancer Center - Carmichael
Carmichael, California · Recruiting
Mercy San Juan Medical Center
Carmichael, California · Recruiting
Enloe Medical Center
Chico, California · Recruiting
Kaiser Permanente Dublin
Dublin, California · Recruiting
Mercy Cancer Center - Elk Grove
Elk Grove, California · Recruiting
Stanford Cancer Center Emeryville
Emeryville, California · Recruiting
Kaiser Permanente-Fremont
Fremont, California · Recruiting
Washington Health
Fremont, California · Recruiting
Kaiser Permanente Fresno Orchard Plaza
Fresno, California · Recruiting
UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care
Irvine, California · Recruiting
UC San Diego Moores Cancer Center
La Jolla, California · Recruiting
Loma Linda University Medical Center
Loma Linda, California · Recruiting
Fremont - Rideout Cancer Center
Marysville, California · Recruiting
Mercy Cancer Center
Merced, California · Suspended
Kaiser Permanente- Modesto MOB II
Modesto, California · Recruiting
Kaiser Permanente-Modesto
Modesto, California · Recruiting
Kaiser Permanente-Oakland
Oakland, California · Recruiting
UC Irvine Health/Chao Family Comprehensive Cancer Center
Orange, California · Recruiting
Stanford Cancer Institute Palo Alto
Palo Alto, California · Recruiting
Huntington Memorial Hospital
Pasadena, California · Recruiting
Eisenhower Medical Center
Rancho Mirage, California · Recruiting
Mercy Cancer Center - Rocklin
Rocklin, California · Recruiting
Kaiser Permanente-Roseville
Roseville, California · Recruiting
Kaiser Permanente Downtown Commons
Sacramento, California · Recruiting
Mercy Cancer Center - Sacramento
Sacramento, California · Recruiting
University of California Davis Comprehensive Cancer Center
Sacramento, California · Recruiting
Kaiser Permanente-South Sacramento
Sacramento, California · Recruiting
Salinas Valley Memorial
Salinas, California · Recruiting
UC San Diego Medical Center - Hillcrest
San Diego, California · Recruiting
Kaiser Permanente-San Francisco
San Francisco, California · Recruiting
Kaiser Permanente-Santa Teresa-San Jose
San Jose, California · Recruiting
Stanford Cancer Center South Bay
San Jose, California · Recruiting
Kaiser Permanente San Leandro
San Leandro, California · Recruiting
Showing 40 of 702 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.